Patients Can Now Connect With 9amHealth's Expert-Led Virtual Clinic Through the NovoCare® Website to Receive Comprehensive Treatment for Chronic Conditions.
9amHealth, a virtual care provider focused on cardiometabolic conditions, announced a new relationship with Novo Nordisk to offer patients access to obesity care across the United States. Through this collaboration, patients can now access 9amHealth's independent, specialist-led virtual clinic through NovoCare.com.
https://mma.prnewswire.com/media/1628937/9amhealth_Logo.jpg
“We're in the midst of a once-in-a-lifetime shift driven by next-generation obesity medications,” said Paul Geevarghese, Co-Founder & Chief Operating Officer at 9amHealth. “People with chronic cardiometabolic conditions are proactively seeking medical care in unprecedented numbers, which creates the opportunity to deliver diagnostics, prevention, lifestyle support, and treatment in one seamless virtual experience. Working with Novo Nordisk allows us to extend that expert care to even more patients nationwide.”
This milestone reflects both organizations' commitment to helping patients with obesity find the care they need via licensed healthcare professionals practicing evidence-basedmedicine. 9amHealth's care model prioritizes patient safety through comprehensive medical evaluations, lab testing, and the avoidance of compounded products that do not undergo FDA review for safety, quality,or effectiveness. It upholds this standard independent of the growing attention to telehealth prescribing practices.
“Every patient deserves access to timely, expert-led care for chronic conditions like obesity, regardless of where they live or how they receive their care,” said Dave Moore, Executive Vice President of US Operations at Novo Nordisk.”By working with 9amHealth, we're helping connect patients who prefer telehealth solutions with healthcare professionals that practice clinically validated care which includes avoiding non-FDA approved knockoff products that may expose patients to serious risks. This collaboration reflects our continued commitment to working with trusted providers who share our standards for quality, safety, and clinical integrity.”
Meeting Patient Needs with High-Quality Virtual Care
Through NovoCare®, patients can now connect with 9amHealth's multidisciplinary clinical team from the comfort of home. Services include:
— Medical evaluation by licensed providers
— At-home lab testing
— Prescription of FDA-approved medications, if medically appropriate
— Personalized nutrition guidance based on the “food as medicine” approach
— Ongoing support from physicians, endocrinologists, obesity specialists, dietitians, and pharmacists
This fully virtual model is designed to deliver high-touch care while preserving rigorous clinical oversight.
The announcement follows the recent launch of a self-pay offer from Novo Nordisk,which now allows eligible patients to access authentic, FDA-approved Wegovy® for $499/month-a flat, transparent price that helps address affordability and deters use of unregulated compounded alternatives.
About 9amHealth
9amHealth offers complete cardiometabolic care-a first-of-its-kind, whole-body approach to preventing and treating obesity, diabetes, high cholesterol, and hypertension. They partner with employers, health plans, and PBMs to provide effective health benefits for those living with chronic conditions. Their members receive personalized care plans, prescription delivery, at-home lab tests, and unlimited specialist access. 9amHealth was founded in 2021 by the team behind mySugr and is backed by 7Wire Ventures, Cigna Ventures, Human Capital, Founders Fund, and Define Ventures. Learn more at www.join9am.com.
https://c212.net/c/img/favicon.png?sn=LA59857&sd=2025-08-27
View original content to download multimedia:https://www.prnewswire.com/news-releases/9amhealth-teams-up-with-novo-nordisk-to-expand-access-to-evidence-based-virtual-obesity-care-nationwide-302539741.html
SOURCE 9amHealth
https://rt.newswire.ca/rt.gif?NewsItemId=LA59857&Transmission_Id=202508270830PR_NEWS_USPR_____LA59857&DateId=20250827